Pharmaron Beijing Co., Ltd. (HKG:3759)

Market Cap	49.27B
Revenue (ttm)	13.06B
Net Income (ttm)	2.09B
Shares Out	n/a
EPS (ttm)	1.18
PE Ratio	23.61
Forward PE	n/a
Dividend	0.22 (1.31%)
Ex-Dividend Date	Jun 27, 2024

Volume	6,454,800
Average Volume	9,308,276
Open	16.72
Previous Close	16.84
Day's Range	15.70 - 16.82
52-Week Range	7.98 - 24.85
Beta	0.89
RSI	55.94
Earnings Date	Mar 27, 2025

About Pharmaron Beijing

Pharmaron Beijing Co., Ltd., together with its subsidiaries, provides drug research and development, and production services to the life sciences industry in North America, Europe, Japan, Mainland China, and internationally. The company offers laboratory chemistry services, including medicinal and synthetic chemistry, chemistry for new modalities, radiolabelling and radiosynthesis, analytical and purification chemistry, DNA-encoded libraries, cheminformatics, and computer-aided drug design; bioscience services, such as structural biology, in vi...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2004
• Employees: 20,295
• Stock Exchange: Hong Kong Stock Exchange
• Ticker Symbol: 3759

Financial Performance

In 2023, Pharmaron Beijing's revenue was 11.54 billion, an increase of 12.39% compared to the previous year's 10.27 billion. Earnings were 1.60 billion, an increase of 16.48%.

Financial numbers in CNY